Key Points
-
Stanley Druckenmiller, managing over $4 billion in assets at Duquesne Family Office, fully exited his stake in Palantir Technologies (NASDAQ: PLTR) over a nine-month period ending March 2025.
-
As of August 15, Palantir’s stock had a price-to-sales (P/S) ratio of approximately 140, raising concerns about its valuation amid market conditions.
-
Druckenmiller has also increased holdings in Teva Pharmaceutical Industries (NYSE: TEVA), making it his fund’s second largest holding with a total of 15,968,935 shares acquired over the last four quarters.
On August 14, the filing deadline for Form 13Fs passed, revealing that Druckenmiller significantly reduced his position in Palantir from nearly 770,000 shares to zero. His fund has preferred investing in Teva, which reported an 87% gain over the last two years. Druckenmiller’s selling of Palantir raises questions about its high valuation and potential market risks as AI stocks evolve.
